Ian Wisenberg
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PsyBio (PSYB) appoints Ian Wisenberg to the Board of Directors
  • Ian Wisenberg will also work as an independent member of the company’s audit committee
  • Wisenberg was also issued the option to purchase 500,000 subordinate voting shares at C$0.05
  • The shares are exercisable until January 9, 2028, subject to certain vesting conditions
  • PsyBio Therapeutics (PSYB) is up 10 per cent, trading at 0.06 at 10:06 am EST

PsyBio Therapeutics (PSYB) has appointed life sciences veteran Ian Wisenberg to the company’s board of directors.

Ian Wisenberg will also work as an independent member of the company’s audit committee.

Wisenberg’s career spans over three decades in the biotechnology international business.

Ian has been an integral leader in charting innovation and growth across several Bridgewest Group biotech companies.

As CEO and board director of BioCina Pty, he is recognized for the company’s strong history as a multi-product biologics development and manufacturer.

Prior to taking the helm at BioCina, Ian was the founder and Chief Business Officer of BioArdis, a preclinical biopharmaceutical development company, and Chief Financial Officer at BioDura.

Ian is originally from Cape Town, South Africa, and attended the University of Cape Town.

Wisenberg was also issued the option to purchase 500,000 subordinate voting shares at C$0.05, being the closing price of the Shares on January 9, 2023.

The shares are exercisable until January 9, 2028, subject to certain vesting conditions.

PsyBio also approved the repricing and expiry date extension of 8,945,800 options previously granted to employees, directors and consultants of the company.

All of the amended options are subject to the approval of the TSXV, and the amended options issued to insiders are subject to disinterested shareholder approval at the next meeting in Q4 of 2023. 

PsyBio Therapeutics is an intellectual property-driven biotechnology company developing novel psycho-targeted therapeutics to be designed to improve mental health and neurological conditions.

PsyBio Therapeutics (PSYB) is up 10 per cent, trading at 0.06 at 10:06 am EST.


More From The Market Herald
Parkview Project in New World Island, Newfoundland

" Lithium One (TSXV:LONE) expands land position in Northwest Ontario

Lithium One Metals (LONE) has signed an agreement to acquire an additional lithium property.

" Candente Copper (TSX:DNT) Closes Private Placement With Fortescue Metals

Candente Copper (DNT) closes the previously announced private placement with Nascent Exploration Fortescue Metals Group, raising $4,000,000.

" BeWhere (TSXV:BEW) launches BeMini asset tracker on Geotab Marketplace

BeWhere (BEW) announced the launch of its BeMini on Geotab’s Marketplace.

" LithiumBank (TSXV:LBNK) to develop Boardwalk and Park Place lithium brine projects

LithiumBank Resources (LBNK) has released key milestones for its Boardwalk and Park Place lithium projects.